CYP3A5 and oculocutaneous albinism type 1: It was demonstrated that while genetic testing for the CYP3A5*3 polymorphism might incur higher initial costs compared to a standard approach [13,28], it remains cost-effective in achieving graft survival without complications like rejection or ATN [9].